New combo therapy aims to control liver cancer without surgery

NCT ID NCT06040099

First seen Nov 06, 2025 · Last updated May 10, 2026 · Updated 22 times

Summary

This study tests whether a two-drug immunotherapy combination (durvalumab and bevacizumab) given after a precise internal radiation treatment (TARE) can help control liver cancer that cannot be removed by surgery. About 58 adults with this type of liver cancer will receive the radiation first, then the drugs. The main goal is to see how long the cancer stays under control and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Aurora, Colorado, 80045, United States

  • Research Site

    Gainesville, Florida, 32608, United States

  • Research Site

    Orlando, Florida, 32804, United States

  • Research Site

    Atlanta, Georgia, 30322, United States

  • Research Site

    Atlanta, Georgia, 30342, United States

  • Research Site

    Chicago, Illinois, 60611, United States

  • Research Site

    Boston, Massachusetts, 02118, United States

  • Research Site

    Detroit, Michigan, 48201, United States

  • Research Site

    St Louis, Missouri, 63110, United States

  • Research Site

    Trenton, New Jersey, 08690, United States

  • Research Site

    Buffalo, New York, 14263, United States

  • Research Site

    New York, New York, 10029, United States

  • Research Site

    Chapel Hill, North Carolina, 27599, United States

  • Research Site

    Columbus, Ohio, 43210, United States

  • Research Site

    Portland, Oregon, 97239, United States

  • Research Site

    Philadelphia, Pennsylvania, 19107, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Charlottesville, Virginia, 22908, United States

  • Research Site

    Seattle, Washington, 98195, United States

  • Research Site

    Milwaukee, Wisconsin, 53215, United States

  • Research Site

    Milwaukee, Wisconsin, 53226, United States

Conditions

Explore the condition pages connected to this study.